CCND1 (Cyclin D1)

Riluzole disrupts mitochondrial homeostasis by increasing Bax/Bcl-2 ratio, resulting in a drop of mitochondrial membrane potential. In conclusion, riluzole inhibits HCC growth by regulating glucose and glutamine metabolism and inducing autophagic cell death, thereby highlighting its therapeutic potential for HCC treatment.

P1, N=48, Active, not recruiting, Nader Sanai | Trial completion date: Mar 2026 --> Mar 2027

The Editor apologizes to the readership for any inconvenience caused. [International Journal of Oncology 54: 17‑28, 2019; DOI: 10.3892/ijo.2018.4600].

Analysis of the effective values of the reactions indicated significant positive linear correlations between the investigated immunomarkers. The reactions were variable in a relatively homogeneous group of PAA and although they were generally associated with aggressive HP behavior, they seem useful in the punctual identification of cases that require a particular management, in the context of specific oncological therapy.

SQYC inhibits CRC progression through NQO1 suppression, ROS activation, and Wnt/β-catenin pathway inhibition. These results provide a novel mechanistic insight of SQYC and highlight its potential as a promising candidate for the clinical treatment of CRC.

This study provides the first comprehensive proteogenomic profile of MCL, offering novel insights into its molecular mechanisms and clinical behavior. The identification of molecular subtypes and prognostic protein signatures underscores the potential of proteomics to guide precision medicine strategies for MCL.

P2, N=40, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026

P2, N=194, Active, not recruiting, The Lymphoma Academic Research Organisation | Recruiting --> Active, not recruiting

Combined invasion and proliferation signatures strongly stratify breast cancer prognosis, underscoring the clinical relevance of this phenotypic interplay. These findings indicate that metastatic competence emerges from the integration of Prrx1 co-regulated molecular programs, explaining why some invasive cells enter dormancy while others resume growth.

Treatment with a rituximab-bevacizumab combination regimen induced a second complete remission, sustained for six months at the time of reporting. Our case highlights the importance of routine CD5 testing in PCDLBCL-LT to identify this distinct subgroup and to guide appropriate differential diagnosis and patient monitoring.

Collectively, our results establish the TWEAK-HOIP-AMPK-HuR axis as a critical signaling axis that couples metabolic dysfunction to dysregulated cell cycle progression in LN. This work not only provides critical new mechanistic insights into the pathogenesis of mesangial hyperproliferation in LN but also highlights potential therapeutic targets, including HOIP and cytoplasmic HuR, for the development of targeted treatments for LN and other renal diseases characterized by abnormal MCs proliferation.